Advertisement

Drugs & Aging

, Volume 36, Issue 1, pp 65–71 | Cite as

Serum Concentrations and Elimination Rates of Direct-Acting Oral Anticoagulants (DOACs) in Older Hip Fracture Patients Hospitalized for Surgery: A Pilot Study

  • Kirsten K. Viktil
  • Ina Lehre
  • Anette H. Ranhoff
  • Espen MoldenEmail author
Short Communication
  • 95 Downloads

Abstract

Background

Use of direct-acting oral anticoagulants (DOACs) is increasing, but knowledge about pharmacokinetics and safety in frail patients is lacking.

Objective

The aim was to determine serum concentrations and elimination rates of DOACs in older hip fracture patients hospitalized for surgery.

Methods

The study included patients ≥ 65 years of age hospitalized for acute hip fracture surgery over a period of 6 months. Use of antithrombotic drugs was registered and serum samples collected for analysis of DOACs (apixaban, dabigatran and rivaroxaban) at admission and surgery. Measured concentrations were assessed in relation to reference (therapeutic) ranges of the respective drugs and applied for half-life calculations. Furthermore, waiting time for surgery was compared between DOAC and warfarin users.

Results

Of 167 patients included (median age 84 years), 11 and 14 used DOACs and warfarin, respectively. Seven of the DOAC-treated patients had concentrations above the upper reference range (> 300 nM) at admission, and concentrations were still in the reference range for five of these at surgery. Elimination half-lives could be estimated in eight patients and ranged between 14.6 and 59.7 h (median 21.6). The observed waiting time for surgery was longer for patients using DOACs than warfarin (median 44 vs. 25 h).

Conclusion

This pilot study indicates that older patients prone to hip fracture are at risk of being exposed to therapeutic serum concentrations of DOACs during surgery due to reduced drug elimination rates. The observation that almost 50% of the patients had therapeutic concentrations at surgery should be investigated further regarding safety of DOAC use in this frail elderly population.

Notes

Acknowledgements

The authors are thankful to physicians and nurses at the orthogeriatric unit who contributed to the patient inclusion, blood sampling and registration of clinical data. We are also grateful to Undis Ellevog at the therapeutic drug monitoring laboratory, for performing serum concentration analyses of DOACs.

Compliance with Ethical Standards

Funding

No external funding was used in the preparation of this manuscript.

Conflict of interest

Authors KKV, IL, AHR and EM declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

References

  1. 1.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefGoogle Scholar
  2. 2.
    Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.CrossRefGoogle Scholar
  3. 3.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.CrossRefGoogle Scholar
  4. 4.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.CrossRefGoogle Scholar
  5. 5.
    Karamichalakis N, Georgopoulos S, Vlachos K, Liatakis I, Efremidis M, Sideris A, Letsas KP. Efficacy and safety of novel anticoagulants in the elderly. J Geriatr Cardiol. 2016;13:718–23.Google Scholar
  6. 6.
    Stollberger C, Finsterer J. Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation. Drugs Aging. 2013;30:949–58.CrossRefGoogle Scholar
  7. 7.
    Stollberger C, Brooks R, Finsterer J, Pachofszky T. Use of direct-acting oral anticoagulants in nonagenarians: a call for more data. Drugs Aging. 2016;33:315–20.CrossRefGoogle Scholar
  8. 8.
    Juliebo V, Bjoro K, Krogseth M, Skovlund E, Ranhoff AH, Wyller TB. Risk factors for preoperative and postoperative delirium in elderly patients with hip fracture. J Am Geriatr Soc. 2009;57:1354–61.CrossRefGoogle Scholar
  9. 9.
    Moja L, Piatti A, Pecoraro V, Ricci C, Virgili G, Salanti G, Germagnoli L, Liberati A, Banfi G. Timing matters in hip fracture surgery: patients operated within 48 hours have better outcomes. A meta-analysis and meta-regression of over 190,000 patients. PLoS One 2012;7:e46175.Google Scholar
  10. 10.
    Simunovic N, Devereaux PJ, Sprague S, Guyatt GH, Schemitsch E, Debeer J, Bhandari M. Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. CMAJ. 2010;182:1609–16.CrossRefGoogle Scholar
  11. 11.
    Ktistakis I, Giannoudis V, Giannoudis PV. Anticoagulation therapy and proximal femoral fracture treatment: an update. EFORT Open Rev. 2016;1:310–5.CrossRefGoogle Scholar
  12. 12.
    Yassa R, Khalfaoui MY, Hujazi I, Sevenoaks H, Dunkow P. Management of anticoagulation in hip fractures: a pragmatic approach. EFORT Open Rev. 2017;2:394–402.CrossRefGoogle Scholar
  13. 13.
  14. 14.
  15. 15.
  16. 16.
    Scullin C, Scott MG, Hogg A, McElnay JC. An innovative approach to integrated medicines management. J Eval Clin Pract. 2007;13:781–8.CrossRefGoogle Scholar
  17. 17.
    Botev R, Mallie JP, Couchoud C, Schuck O, Fauvel JP, Wetzels JF, Lee N, De Santo NG, Cirillo M. Estimating glomerular filtration rate: Cockcroft-Gault and Modification of Diet in Renal Disease formulas compared to renal inulin clearance. Clin J Am Soc Nephrol. 2009;4:899–906.CrossRefGoogle Scholar
  18. 18.
    Lundgaard H, Dyrkorn R, Stokes CL, Molden E, Spigset O. Safer treatment with serum concentration monitoring of the new anticoagulants? Tidsskr Nor Laegeforen. 2016;136:1556–60 (Readers may contact the authors for an English translation of key points in the paper).Google Scholar
  19. 19.
    Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ. 2014;349:g4670.CrossRefGoogle Scholar
  20. 20.
    Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63:321–8.CrossRefGoogle Scholar
  21. 21.
    Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29:S24–33.CrossRefGoogle Scholar
  22. 22.
    Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53:1–16.CrossRefGoogle Scholar
  23. 23.
    Skeppholm M, Al-Aieshy F, Berndtsson M, Al-Khalili F, Ronquist-Nii Y, Soderblom L, Ostlund AY, Pohanka A, Antovic J, Malmstrom RE. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb Res. 2015;136:148–53.CrossRefGoogle Scholar
  24. 24.
    Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131–41.CrossRefGoogle Scholar
  25. 25.
    Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377:431–41.CrossRefGoogle Scholar
  26. 26.
    Urbaniak AM, Strom BO, Krontveit R, Svanqvist KH. Prescription patterns of non-vitamin K oral anticoagulants across indications and factors associated with their increased prescribing in atrial fibrillation between 2012–2015: a study from the Norwegian Prescription Database. Drugs Aging. 2017;34:635–45.CrossRefGoogle Scholar
  27. 27.
    Hartter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa((R))) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol. 2013;75:1053–62.CrossRefGoogle Scholar
  28. 28.
    Wakasugi H, Yano I, Ito T, Hashida T, Futami T, Nohara R, Sasayama S, Inui K. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther. 1998;64:123–8.CrossRefGoogle Scholar
  29. 29.
    Gupta S. P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy. Drugs Aging. 1995;7:19–29.Google Scholar
  30. 30.
    Toornvliet R, van Berckel BN, Luurtsema G, Lubberink M, Geldof AA, Bosch TM, Oerlemans R, Lammertsma AA, Franssen EJ. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther. 2006;79:540–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Diakonhjemmet Hospital PharmacyOsloNorway
  2. 2.School of PharmacyUniversity of OsloOsloNorway
  3. 3.Departments of Medicine and SurgeryDiakonhjemmet HospitalOsloNorway
  4. 4.Department of Clinical ScienceUniversity of BergenBergenNorway
  5. 5.Therapeutic Drug Monitoring Unit, Center for PsychopharmacologyDiakonhjemmet HospitalOsloNorway

Personalised recommendations